RARE — Ultragenyx Pharmaceutical Inc.

Summary of Ultragenyx Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $136 million for Q1 2026.
  • Crysvita: $93 million (North America: $39 million, Latin America and Turkey: $46 million, Europe: $8 million).
  • Dojolvi: $18 million, consistent with steady growth.
  • Evkeeza: $18 million, representing a 64% increase year-over-year.
  • Mepsevii: $7 million.
• Operating Expenses: $305 million, including $30 million in cost of sales and $275 million in combined R&D and SG&A expenses.
• Net Loss: $185 million, or $1.84 per share.
• Cash Position: $534 million in cash, cash equivalents, and marketable securities.
• Net Cash Used in Operations: $197 million, expected to decrease in subsequent quarters.

2. Strategic Updates and Business Highlights

• Transformative Year: 2026 is expected to be transformative with anticipated revenue exceeding $700 million and multiple new drug approvals.
• Gene Therapy Developments: PDUFA dates set for GTX-102 (Angelman syndrome), DTX401, and UX111, with the latter two expected to launch in late 2026.
• Clinical Trials: Continued enrollment in the Phase 3 Aspire study for GTX-102, with promising long-term data showing benefits for patients.
• Global Commercialization: Revenue generation in over 35 countries, with a focus on building a robust commercial infrastructure to support new product launches.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Reaffirmed guidance of $730 million to $760 million, reflecting 8% to 13% growth over 2025.
• Crysvita Revenue Expectation: Projected between $500 million and $520 million.
• Dojolvi Revenue Expectation: Projected between $100 million and $110 million.
• R&D and SG&A Expenses: Expected to remain flat or decrease slightly compared to 2025.

4. Bad News, Challenges, or Points of Concern

• High Operating Expenses: Total operating expenses remain significant, leading to a substantial net loss.
• Discontinuation Rates: While currently low, there are concerns about potential patient discontinuations due to the burden of study participation in clinical trials.
• Regulatory Risks: The success of upcoming product launches and the ability to navigate complex reimbursement processes pose ongoing risks.
• Market Competition: The company is focused on rare diseases with limited competition, but the landscape remains challenging with the influx of late-stage programs.

5. Notable Q&A Insights

• MDRI vs. Bayley-4 Cognition: The company expressed more confidence in the MDRI as a robust measure for assessing treatment efficacy in Angelman syndrome, while acknowledging the Bayley-4 as a critical endpoint.
• Sham Performance in Trials: Management is confident that sham performance will not significantly affect outcomes in the Aspire study, based on historical data.
• Discontinuation Management: Plans are in place to minimize discontinuation rates in the commercial setting, focusing on patient convenience and support.
• PRV Monetization: The company plans to monetize two Priority Review Vouchers (PRVs) from upcoming launches, which could provide additional financial upside.

Overall, Ultragenyx is positioned for growth with a strong pipeline and strategic focus on rare diseases, despite facing challenges related to high operating costs and regulatory complexities.